- Home
- All Stock List
- NSE
- Suraksha Diagnostic Ltd Share Price
259.20
-1.80 (-0.69%)
-
Underperforms Index
0%
Return (1Y)
Underperformed Nifty 50 by 5.34%
-
More Volatile
2.72%
Standard Deviation (1Y)
Higher than Nifty 50 by 1.83%
-
Inconsistent Performer
0/4
Months
underperformed Nifty 50
-
AxisDirect View
No View
449
231
News & Announcements
-
Suraksha Diagnostic slips after CFO resigns
41 days ago
The company stated, Due to personal reasons, Amit Saraf, CFO and KMP of the company, has resigned from the services of the company w.e.f. 15.02.2025.
The shares of Suraksha Diagnostic entered the stock market on 6 December 2024. The scrip was listed at Rs 437, exhibiting a discount of 0.91% to the issue price of Rs 441.
Suraksha Diagnostic is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network.
The company reported a 32.25% jump in consolidated net profit to Rs 6.15 crore in Q3 FY25, compared with Rs 4.65 crore in Q3 FY24. Revenue from operations increased 14.83% YoY to Rs 59.51 crore during the quarter ended 31 December 2024.
Powered by Capital Market - Live News
-
Suraksha Diagnostic consolidated net profit rises 32.26% in the December 2024 quarter
10 - Feb - 2025 12:00 | 49 days ago
Net profit of Suraksha Diagnostic rose 32.26% to Rs 6.15 crore in the quarter ended December 2024 as against Rs 4.65 crore during the previous quarter ended December 2023. Sales rose 14.84% to Rs 59.51 crore in the quarter ended December 2024 as against Rs 51.82 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 59.51 51.82 15 OPM % 30.68 29.54 - PBDT 16.87 14.14 19 PBT 8.05 6.22 29 NP 6.15 4.65 32 Powered by Capital Market - Live News
-
Suraksha Diagnostic to table results
56 days ago
-
Suraksha Diagnostic consolidated net profit rises 32.26% in the December 2024 quarter
10 - Feb - 2025 12:00 | 49 days ago
Net profit of Suraksha Diagnostic rose 32.26% to Rs 6.15 crore in the quarter ended December 2024 as against Rs 4.65 crore during the previous quarter ended December 2023. Sales rose 14.84% to Rs 59.51 crore in the quarter ended December 2024 as against Rs 51.82 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 59.51 51.82 15 OPM % 30.68 29.54 - PBDT 16.87 14.14 19 PBT 8.05 6.22 29 NP 6.15 4.65 32 Powered by Capital Market - Live News
-
Suraksha Diagnostic to table results
56 days ago
-
Revenue from operations increased 11.18% YoY to Rs 66.75 crore during the quarter ended 30 September 2024.
Profit before tax (PBT) jumped 24.36% YoY to Rs 13.63 crore in Q2 FY25.
In Q2 FY25, EBITDA stood at Rs 24.51 crore, registering the growth of 14.6% as compared with Rs 21.39 crore posted in corresponding quarter last year. EBITDA margin stood at 36.7% in Q2 FY25 as against 35.6% in Q2 FY24.
As of September 2024, the company’s consolidated net cash stood at Rs 49.83 crore compared to Rs 46.38 crore at the end of FY24
Ritu Mittal, joint managing director & CEO said, “Our focus on operational efficiency, revenue growth, has translated into robust results, reflecting our ability to navigate the business landscape effectively.
Over the years, we have been able to drive consistent improvement in revenue per patient and EBITDA per patient which stood at Rs 2,099 and Rs 761, respectively in H1 FY25. We believe we are on a solid footing to win, given the changing customer preference towards organized diagnostic chains from standalone centres.
West Bengal continues to be the prominent market for our company, with 47 out of the total 51 centers located in the state. We remain committed in our endeavor to drive further growth from the Eastern and North-Eastern markets in India. We believe the strong results position us well to drive sustainable top-line and margin growth.
As a publicly listed entity, we remain committed to enhancing shareholder value by executing on our welldefined strategies to expand into our core markets and also exploring inorganic growth opportunities. In conclusion, I would like to thank all stakeholders, past and present, and hope for continued support as we strive to reach scale newer summits.”
The shares of Suraksha Diagnostic entered into the stock market on 6 December 2024. The scrip was listed at Rs 437, exhibiting a discount of 0.91% to the issue price of Rs 441.
Suraksha Diagnostic is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network.
The scrip declined 1.98% to Rs 404.45 on the BSE.
Powered by Capital Market - Live News
-
Suraksha Diagnostic slips after CFO resigns
41 days ago
The company stated, Due to personal reasons, Amit Saraf, CFO and KMP of the company, has resigned from the services of the company w.e.f. 15.02.2025.
The shares of Suraksha Diagnostic entered the stock market on 6 December 2024. The scrip was listed at Rs 437, exhibiting a discount of 0.91% to the issue price of Rs 441.
Suraksha Diagnostic is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network.
The company reported a 32.25% jump in consolidated net profit to Rs 6.15 crore in Q3 FY25, compared with Rs 4.65 crore in Q3 FY24. Revenue from operations increased 14.83% YoY to Rs 59.51 crore during the quarter ended 31 December 2024.
Powered by Capital Market - Live News
-
Suraksha Diagnostic consolidated net profit rises 32.26% in the December 2024 quarter
10 - Feb - 2025 12:00 | 49 days ago
Net profit of Suraksha Diagnostic rose 32.26% to Rs 6.15 crore in the quarter ended December 2024 as against Rs 4.65 crore during the previous quarter ended December 2023. Sales rose 14.84% to Rs 59.51 crore in the quarter ended December 2024 as against Rs 51.82 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 59.51 51.82 15 OPM % 30.68 29.54 - PBDT 16.87 14.14 19 PBT 8.05 6.22 29 NP 6.15 4.65 32 Powered by Capital Market - Live News
-
Suraksha Diagnostic to table results
56 days ago
-
Revenue from operations increased 11.18% YoY to Rs 66.75 crore during the quarter ended 30 September 2024.
Profit before tax (PBT) jumped 24.36% YoY to Rs 13.63 crore in Q2 FY25.
In Q2 FY25, EBITDA stood at Rs 24.51 crore, registering the growth of 14.6% as compared with Rs 21.39 crore posted in corresponding quarter last year. EBITDA margin stood at 36.7% in Q2 FY25 as against 35.6% in Q2 FY24.
As of September 2024, the company’s consolidated net cash stood at Rs 49.83 crore compared to Rs 46.38 crore at the end of FY24
Ritu Mittal, joint managing director & CEO said, “Our focus on operational efficiency, revenue growth, has translated into robust results, reflecting our ability to navigate the business landscape effectively.
Over the years, we have been able to drive consistent improvement in revenue per patient and EBITDA per patient which stood at Rs 2,099 and Rs 761, respectively in H1 FY25. We believe we are on a solid footing to win, given the changing customer preference towards organized diagnostic chains from standalone centres.
West Bengal continues to be the prominent market for our company, with 47 out of the total 51 centers located in the state. We remain committed in our endeavor to drive further growth from the Eastern and North-Eastern markets in India. We believe the strong results position us well to drive sustainable top-line and margin growth.
As a publicly listed entity, we remain committed to enhancing shareholder value by executing on our welldefined strategies to expand into our core markets and also exploring inorganic growth opportunities. In conclusion, I would like to thank all stakeholders, past and present, and hope for continued support as we strive to reach scale newer summits.”
The shares of Suraksha Diagnostic entered into the stock market on 6 December 2024. The scrip was listed at Rs 437, exhibiting a discount of 0.91% to the issue price of Rs 441.
Suraksha Diagnostic is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network.
The scrip declined 1.98% to Rs 404.45 on the BSE.
Powered by Capital Market - Live News
-
Suraksha Diagnostic slips after CFO resigns
41 days ago
The company stated, Due to personal reasons, Amit Saraf, CFO and KMP of the company, has resigned from the services of the company w.e.f. 15.02.2025.
The shares of Suraksha Diagnostic entered the stock market on 6 December 2024. The scrip was listed at Rs 437, exhibiting a discount of 0.91% to the issue price of Rs 441.
Suraksha Diagnostic is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network.
The company reported a 32.25% jump in consolidated net profit to Rs 6.15 crore in Q3 FY25, compared with Rs 4.65 crore in Q3 FY24. Revenue from operations increased 14.83% YoY to Rs 59.51 crore during the quarter ended 31 December 2024.
Powered by Capital Market - Live News
-
Suraksha Diagnostic consolidated net profit rises 32.26% in the December 2024 quarter
10 - Feb - 2025 12:00 | 49 days ago
Net profit of Suraksha Diagnostic rose 32.26% to Rs 6.15 crore in the quarter ended December 2024 as against Rs 4.65 crore during the previous quarter ended December 2023. Sales rose 14.84% to Rs 59.51 crore in the quarter ended December 2024 as against Rs 51.82 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 59.51 51.82 15 OPM % 30.68 29.54 - PBDT 16.87 14.14 19 PBT 8.05 6.22 29 NP 6.15 4.65 32 Powered by Capital Market - Live News
-
Suraksha Diagnostic to table results
56 days ago
-
Suraksha Diagnostic consolidated net profit rises 32.26% in the December 2024 quarter
10 - Feb - 2025 12:00 | 49 days ago
Net profit of Suraksha Diagnostic rose 32.26% to Rs 6.15 crore in the quarter ended December 2024 as against Rs 4.65 crore during the previous quarter ended December 2023. Sales rose 14.84% to Rs 59.51 crore in the quarter ended December 2024 as against Rs 51.82 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 59.51 51.82 15 OPM % 30.68 29.54 - PBDT 16.87 14.14 19 PBT 8.05 6.22 29 NP 6.15 4.65 32 Powered by Capital Market - Live News
-
Suraksha Diagnostic to table results
56 days ago
-
Revenue from operations increased 11.18% YoY to Rs 66.75 crore during the quarter ended 30 September 2024.
Profit before tax (PBT) jumped 24.36% YoY to Rs 13.63 crore in Q2 FY25.
In Q2 FY25, EBITDA stood at Rs 24.51 crore, registering the growth of 14.6% as compared with Rs 21.39 crore posted in corresponding quarter last year. EBITDA margin stood at 36.7% in Q2 FY25 as against 35.6% in Q2 FY24.
As of September 2024, the company’s consolidated net cash stood at Rs 49.83 crore compared to Rs 46.38 crore at the end of FY24
Ritu Mittal, joint managing director & CEO said, “Our focus on operational efficiency, revenue growth, has translated into robust results, reflecting our ability to navigate the business landscape effectively.
Over the years, we have been able to drive consistent improvement in revenue per patient and EBITDA per patient which stood at Rs 2,099 and Rs 761, respectively in H1 FY25. We believe we are on a solid footing to win, given the changing customer preference towards organized diagnostic chains from standalone centres.
West Bengal continues to be the prominent market for our company, with 47 out of the total 51 centers located in the state. We remain committed in our endeavor to drive further growth from the Eastern and North-Eastern markets in India. We believe the strong results position us well to drive sustainable top-line and margin growth.
As a publicly listed entity, we remain committed to enhancing shareholder value by executing on our welldefined strategies to expand into our core markets and also exploring inorganic growth opportunities. In conclusion, I would like to thank all stakeholders, past and present, and hope for continued support as we strive to reach scale newer summits.”
The shares of Suraksha Diagnostic entered into the stock market on 6 December 2024. The scrip was listed at Rs 437, exhibiting a discount of 0.91% to the issue price of Rs 441.
Suraksha Diagnostic is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network.
The scrip declined 1.98% to Rs 404.45 on the BSE.
Powered by Capital Market - Live News
Stock Trivia
Promoter shareholding in Suraksha Diagnostic Ltd has decreased by -20.11% since past 3 Months
Promoter shareholding in Suraksha Diagnostic Ltd has decreased by -20.11% since past 3 Months
Promoter shareholding in Suraksha Diagnostic Ltd has decreased by -20.11% since past 3 Months
Promoter shareholding in Suraksha Diagnostic Ltd has decreased by -20.11% since past 3 Months
Promoter shareholding in Suraksha Diagnostic Ltd has decreased by -20.11% since past 3 Months
